Combination treatment with ribavirin and interferon for coxsackievirus B3 replication

J Lab Clin Med. 1992 Oct;120(4):569-73.

Abstract

The effects of combined treatment with ribavirin and recombinant human leukocyte interferon-alpha A/D against Coxsackievirus B3 replication were investigated in cultured cells. Recombinant human leukocyte interferon-alpha A/D was applied 12 hours before Coxsackievirus B3 inoculation and ribavirin was applied 1 hour after Coxsackievirus B3 inoculation on FL (human amnion) cell monolayers. These drugs inhibited Coxsackievirus B3 replication synergistically by plaque-reduction assay. This method of applying drugs may be useful in preventing and treating Coxsackie B virus infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line
  • Drug Synergism
  • Enterovirus B, Human / drug effects*
  • Enterovirus B, Human / physiology*
  • Humans
  • Interferon Type I / administration & dosage
  • Interferon Type I / pharmacology*
  • Recombinant Proteins
  • Ribavirin / administration & dosage
  • Ribavirin / pharmacology*
  • Virus Replication / drug effects*

Substances

  • Interferon Type I
  • Recombinant Proteins
  • Ribavirin